F096 Malignant Melanoma: Molecular Diagnostics, Emerging Therapies, and the Microbiome
DESCRIPTION
The session will combine formal lectures and interactive presentations. Different melanoma types and borderline melanocytic lesions will be discussed, in light of the current WHO classification, emphasizing a combined approach utilizing clinico-pathological presentation and new molecular techniques. Novel therapies will also be discussed including targeted therapy and immunotherapy, with emphasis on their efficacy and side effects. The session will also look to the future of melanoma and the impact of the microbiome on prognosis and response to therapy. The session will be directed to general dermatologists, dermato-oncologists, and dermatopathologists. The participants will be actively engaged through the Audience Response System.
LEARNING OBJECTIVES
Recognize the morphology and molecular pathology of different melanoma sub-types and borderline lesions according to the WHO classification system, and determine the appropriate patient management algorithms.
Discuss available molecular tests for diagnosis and prognosis and their application. Discuss new treatment options such as targeted therapy, immune blockade therapy, neoantigen therapy and combination therapies, and the management of their side effects.
Describe and discuss the microbiome as well as its potential import on melanoma diagnosis and response to therapy.
SCHEDULE
3:30 PM
Melanoma Classification and Diagnosis
Iwei Yeh, MD, PhD, FAAD
3:55 PM
Ancillary Molecular Testing
Emily Y. Chu, MD, PhD, FAAD
4:25 PM
Emerging Therapies for Melanoma
Zeynep Eroglu, MD
4:55 PM
Microbiome and Melanoma
Alexander J. F. Lazar, MD, PhD
DIRECTOR
Iwei Yeh, MD, PhD, FAAD
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
Zeynep Eroglu, MD
Alexander J. F. Lazar, MD, PhD
HANDOUTS
DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Zeynep Eroglu, MD
Boehringer Ingelheim – Investigator(Grants/Research Funding); Incyte – Advisory Board(Honoraria); Natera – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Replimune – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Alexander J. F. Lazar, MD, PhD
No financial relationships exist with ineligible companies.
Iwei Yeh, MD, PhD, FAAD
Pfizer Inc. – Investigator(Grants/Research Funding);